Howeedy A A, Virtanen I, Laitinen L, Gould N S, Koukoulis G K, Gould V E
Department of Pathology, Rush Medical College, Chicago, Illinois.
Lab Invest. 1990 Dec;63(6):798-806.
We studied by immunohistochemistry the distribution of tenascin with the monoclonal antibody 100EB2, and compared it with that of laminin in breast tissue samples from fetal, adult resting, lactating, and aging parenchyma, variants of fibrocystic disease, fibroadenomas, cystosarcoma phylloides, and ductal and lobular carcinomas. Monoclonal antibodies were applied to cryosections by the avidin-biotin-complex method; selected samples were studied by double immunofluorescence, and by Western blot analysis. In adult resting and aging breasts, tenascin immunoreactivity was noted in the periductal and periacinar stromal regions as thin irregular bands; in the lactating breast, broader periductal bands were observed. In these samples, laminin immunoreactivity was a single continuous line around ducts, acini, and vessels. In fetal breasts, tenascin appeared as thick periductal bands, whereas laminin remained as a delicate single line. In FCD, tenascin increased around ducts showing hyperplasia, papillomas and apocrine metaplasia, whereas laminin retained its delicate linear pattern. Similar patterns were seen in fibroadenomas and cystosarcoma phylloides with variable tenascin reactivity in the stroma beyond the ducts. Tenascin immunoreactivity was markedly increased around ducts containing in situ carcinoma appearing as broad bands, whereas that of laminin showed a linear, frequently discontinuous appearance. Prominent stromal tenascin immunoreactivity was seen in infiltrating ductal and lobular carcinomas, whereas laminin was virtually absent save for scattered lines. The abundance of tenascin in the carcinomatous stroma contrasted with its scarcity in the non-neoplastic stromal regions. By Western blotting, both chains of tenascin with molecular weights 250,000 and 180,000 were shown in ductal and lobular carcinomas as well as in normal breast. Tenascin immunoreactivity was noted in the periepithelial stromal regions of adult resting and aging breast ducts and acini. The amount of tenascin was moderately enhanced in certain physiologic conditions (fetal growth, gestation), as well as hyperplasias, dysplasias (fibrocystic disease) and benign tumors, whereas it was markedly enhanced in intraductal and infiltrating carcinomas. During fetal mammary development, adult physiologic and pathologic hyperplasias, and in carcinomas, the increasing tenascin reactivity contrasted with the stable or decreasing laminin reactivity.
我们采用免疫组织化学方法，用单克隆抗体100EB2研究了腱生蛋白的分布，并将其与层粘连蛋白在胎儿、成年静止期、哺乳期和衰老期乳腺组织样本、纤维囊性疾病变体、纤维腺瘤、叶状囊肉瘤以及导管癌和小叶癌中的分布进行了比较。通过抗生物素蛋白-生物素复合物法将单克隆抗体应用于冷冻切片；对选定的样本进行了双重免疫荧光和蛋白质印迹分析。在成年静止期和衰老期乳腺中，腱生蛋白免疫反应性在导管周围和腺泡周围的基质区域呈细的不规则条带；在哺乳期乳腺中，观察到较宽的导管周围条带。在这些样本中，层粘连蛋白免疫反应性在导管、腺泡和血管周围呈单一连续线。在胎儿乳腺中，腱生蛋白表现为较厚的导管周围条带，而层粘连蛋白仍为纤细的单线。在纤维囊性疾病中，腱生蛋白在出现增生、乳头状瘤和大汗腺化生的导管周围增加，而层粘连蛋白保持其纤细的线性模式。在纤维腺瘤和叶状囊肉瘤中也观察到类似模式，导管外基质中的腱生蛋白反应性各不相同。在原位癌所在的导管周围，腱生蛋白免疫反应性明显增加，呈宽带状，而层粘连蛋白的免疫反应性呈线性，常不连续。在浸润性导管癌和小叶癌中可见明显的基质腱生蛋白免疫反应性，而层粘连蛋白除散在的线条外几乎不存在。癌性基质中腱生蛋白丰富，与其在非肿瘤性基质区域的稀少形成对比。通过蛋白质印迹法，在导管癌和小叶癌以及正常乳腺中均显示出分子量为250,000和180,000的腱生蛋白两条链。在成年静止期和衰老期乳腺导管和腺泡的上皮周围基质区域发现腱生蛋白免疫反应性。在某些生理状况（胎儿生长、妊娠）以及增生、发育异常（纤维囊性疾病）和良性肿瘤中，腱生蛋白的量适度增加，而在导管内癌和浸润性癌中则明显增加。在胎儿乳腺发育、成年生理和病理增生以及癌中，腱生蛋白反应性增加，而层粘连蛋白反应性稳定或降低，两者形成对比。
